A Selection of Recent Papers

Secondary Structure at a Hot Spot for DNA Methylation in DNA from Human Breast Cancers. J. CLARK, S.S. SMITH (Duarte, CA, USA)


Tissue Microarrays of Human Tumor Xenografts: Characterization of Proteins Involved in Migration and Angiogenesis for Applications in the Development of Targeted Anticancer Agents. V. SMITH, G.J. WIRTH, H.-H. FIEBIG, A.M. BURGER (Freiburg, Germany; Geneva, Switzerland; Detroit, MI, USA)

Ochratoxin A Lowers mRNA Levels of Genes Encoding for Key Proteins of Liver Metabolism. C. HUNDHAUSEN, C. BOESCH-SAADATMANDI, N. MATZNER, F. LANG, R. BLANK, S. WOLFFRAM, W. BLASCHEK, G. RIMBACH (Kiel; Tuebingen, Germany)

Immune Response Signatures of Benzo(a)pyrene Exposure in Normal Human Mammary Epithelial Cells in the Absence or Presence of Chlorophyllin. K. JOHN, C. KESHAVA, D.L. RICHARDSON, A. WESTON, J. NATH (Morgantown, WV, USA)

The Protein Expression of TRP-1 and Galectin-1 in Cutaneous Malignant Melanomas. Å. BOLANDER, M.A. AGNARSDÓTTIR, S. STRÖMBERG, F. PONTEN, P. HESSELIUS, M. UHLEN, M. BERGQVIST (Uppsala; Stockholm, Sweden)


Relative Quantification of Cytochrome P450 1B1 Gene Expression in Peripheral Leukocytes using LightCycler. S. HELMIG, B. HADZAAD, J. DÖHREL, J. SCHNEIDER (Giessen, Germany)

Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients. N. FATIMA, D. CHELIUS, B.T. LUKE, M. YI, T. ZHANG, S. STAUFFER, R. STEPHENS, P. LYNCH, K. MILLER, T. GUSZCZYNSKI, D. BORING, P. GREENWALD, I.U. ALI (Bethesda; Frederick, MD; San Jose, CA; Houston, TX, USA)


Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. S.M. BOKOBZA, L. YE, H.E. KYNASTON, R.E. MANSEL, W.G. JIANG (Cardiff, UK)


Genomic Analysis of Prostate Cancer Stem Cells Isolated from a Highly Metastatic Cell Line. R.A. ROWEHL, H. CRAWFORD, A. DUFOUR, J. JU, G.I. BOTCHKINA (Stony Brook, NY, USA)
Instructions to Authors

**General Policy.** ANTICANCER RESEARCH (AR) will accept high quality original works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy advises that priority should be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis and therapy. AR will also accept the following for publication: (a) abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) announcements of meetings related to cancer research; (c) short reviews (of approximately 1,200 words) and announcements of newly published books and journals related to cancer; and (d) announcements of awards and prizes.

The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in AR, for public archiving in PubMed Central.

A main aim of AR is to ensure the prompt publication of high quality original works, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on cancer that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts in terms of grammar and style.

**Format.** Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all the essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced page), including abstract, text, tables, figures and references (corresponding to 4 printed pages). Papers exceeding four (4) printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, indication of the study type "clinical", "epidemiological", or "experimental", and date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

**Figures.** All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column, 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should be numbered with Arabic numerals and include a short title, and legend if appropriate.

**Tables.** Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title, and legend if appropriate.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.


**Submission of Manuscripts.** You can send your article via e-mail to journals@iiar-anticancer.org, indicating in which journal you wish to be submitted (ANTICANCER RESEARCH, IN VIVO or CANCER GENOMICS & PROTEOMICS). The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments. OR You can send the manuscript of your article via regular mail in a usb stick, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address: Dr. J.G. Delinassios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS, 1st km Kapanadriou-Kalamou Road, P.O. Box 22, GR-19014, Kapanordi, Attiki, Greece. Submitted articles will not be returned to Authors upon rejection.

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

**Reprints.** Twenty-five copies of each published article will be provided free-of-charge. Additional copies may be ordered after acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.
G2-Phase Arrest Through p21/WAF1/Cip1 Induction and cdc2 Repression by Gnidimacrin in Human Hepatoma HLE Cells. M. YOSHIDA, Y. MATSUI, A. IIZUKA, Y. IKARASHI (Tokyo, Japan) ................................................................. 1349


Colon Cancer and Protein Arginine Methyltransferase 1 Gene Expression. A. PAPADOKOSTOPOULOU, K. MATIHOUDAKI, A. SCORILAS, D. XYNOPOULOS, A. ARDAVANIS, E. KOUROJMALIS, M. TALIERI (Athens; Heraklion, Greece) .......................................................................................................................... 1361

siRNA Targeting HIF-1α Induces Apoptosis of Pancreatic Cancer Cells through NF-κB-independent and -dependent Pathways under Hypoxic Conditions. C. CHEN, Z. YU (TianJin, China; Stockholm, Sweden) .............. 1367


Mannose-6-Phosphate/Insulin-like Growth Factor-II Receptor in Human Melanoma Cells: Effect of Ligands and Antibodies on the Receptor Expression. F. LAUBE (Halle, Germany) ........................................................................................................................... 1383

Bladder Cancer and Polymorphisms of DNA Repair Genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). K.F. NARTER, A. ERGEN, B. AĞÇAHAN, U. GÖRMÜŞ, Ö. TIMİRCİ, T. ISBİR (Istanbul, Turkey) ...................... 1389

ARE-I Polymorphism on PSA Gene in Prostate Cancer Patients of a Turkish Population. E. KALAY, A. ERGEN, F. NARTER, B. AĞÇAHAN, U. GÖRMÜŞ, N. YİĞİT, T. ISBİR (Istanbul, Turkey) ........................................... 1395


Effects of Quercetin on the Pharmacokinetics of Etoposide after Oral or Intravenous Administration of Etoposide in Rats. X. LI, J.-S. CHOI (Jilin, China; Gwangju, South Korea) ................................................................. 1411

Anti-proliferative and Apoptosis Induction Activity of Green Tea Polyphenols on Human Promyelocytic Leukemia HL-60 Cells. D.H. HAN, J.H. JEONG, J.H. KIM (Seoul, South Korea) ......................................................................................... 1417

Pro-apoptosis and Anti-proliferation Effects of a Recombinant Dominant-negative Survivin-T34A in Human Cancer Cells. C. SHEN, W. LIU, A.K. BUCK, S.N. RESKE (Ulm, Germany; Huaihua, China) ......................................................................................... 1423

Cytotoxicity and Cellular Uptake of Doxorubicin and its Formamidine Derivatives in HL60 Sensitive and HL60/MX2 Resistant Cells. K. KIK, M. WASOWSKA-LUKAWSKA, I. OSZCZAPOWICZ, L. SZMIGIERO (Lodz; Warsaw, Poland) .................................................. 1429

(-)-Epigallocatechin Gallate Induced Apoptosis in Human Adrenal Cancer NCI-H295 Cells through Caspase-dependent and Caspase-independent Pathway. P.-P. WU, S.-C. KUO, W.-W. HUANG, J.-S. YANG, K.-C. LAI, H.-J. CHEN, K.-L. LIN, Y.-J. CHIU, L.-J. HUANG, J.-G. CHUNG (Taichung; Yunlin; Tainan, Taiwan, ROC) .......... 1435

Novel Therapy for Malignant Pleural Mesothelioma Based on Anti-energetic Effect: An Experimental Study Using 3-Bromopyruvate on Nude Mice. X. ZHANG, E. VARIN, M. BRIAND, S. ALLOUCHE, N. HEUTTE, L. SCHWARTZ, L. POULAIN, P. ICARD (Caen; Saclay, France; Guangxi, China) ................................................................................................. 1443

Intracellular Glutathione Regulates Sesquiterpene Lactone-induced Conversion of Autophagy to Apoptosis in Human Leukemia HL60 Cells. T. ITOH, K. OHGUUCHI, Y. NOZAWA, Y. AKAO (Gifu, Japan) ................................................................. 1449

Immunohistochemical Staining of Ki-67 Using the Monoclonal Antibody Ki-S11 Is a Prognostic Indicator for Laryngeal Squamous Cell Carcinoma. C. CORDES, A.-K. MÜNZEL, P. RUDOLPH, M. HOFFMANN, I. LEUSCHNER, S. GOTTSCHLICH (Kiel, Germany) ................................................................. 1459

* Review (pages 1031, 1095, 1151)
Gene Mutations in Esophageal Mucosa of Chagas Disease Patients. F. DA S. MANOEL-CAETANO, A.F.P. SILVEIRA, A.E. SILVA (São José do Rio Preto, SP, Brazil) ......................................................... 1243

Effect of Citrate on Malignant Pleural Mesothelioma Cells: A Synergistic Effect with Cisplatin. X. ZHANG, E. VARIN, S. ALLOUCHE, Y. LU, L. POULAIN, P. ICARD (Caen, France; Guangxi, China) .................. 1249

Molecular Characterization of Permanent Cell Lines from Primary, Metastatic and Recurrent Malignant Peripheral Nerve Sheath Tumors (MPNST) with Underlying Neurofibromatosis-1. Y. FANG, A. ELAHI, R.C. DENLEY, P.H. RAO, M.F. BRENNAN, S.C. JHANWAR (New York, NY; Tampa, FL; Houston, TX, USA) ...... 1255

Effects of Cepharanthine Alone and in Combination with Fluoropyrimidine Anticancer Agent, S-1, on Tumor Growth of Human Oral Squamous Cell Carcinoma Xenografts in Nude Mice. K. HARADA, T. FERDOUS, Y. ITASHIKI, M. TAKII, T. MANO, Y. MORI, Y. UEYAMA (Yamaguchi; Tokushima, Japan) ........................... 1263

Association of GNB4 Intron-1 Haplotypes with Survival in Patients with UICC Stage III and IV Colorectal Carcinoma. K. Riemann, H. STRUWE, H. ALAKUS, B. OBERMAIER, K.J. SCHMITZ, K.W. SCHMID, W. SIFFERT (Essen; Cologne; Martinsried, Germany) .......................................................... 1271


The Role of the Homeobox Genes BFT and CDX2 in the Pathogenesis of Non-small Cell Lung Cancer. P. Grimminger, F.C. LING, S. NEISS, D. VALLBÖHMER, G. LURJE, P.M. SCHNEIDER, A. H. HÖLSCHER, R. METZGER, J. BRABENDER (Cologne, Germany; Zurich, Switzerland) ................ 1281


In Vivo Modulation of Angiogenic Gene Expression by Acyclic Nucleoside Phosphonates PMEDAP and PMEG. B. OTOVÁ, J. HRDÝ, I. VOTRUBA, A. HOLÝ (Prague, Czech Republic) .................................................. 1295

Declined Asparagine Synthetase mRNA Expression and Enhanced Sensitivity to Asparaginase in HL-60 Cells Committed to Monocytic Differentiation. K. HASHIMOTO, F. SUZUKI, H. SAKAGAMI (Saitama, Japan) ... 1303


Both AP-1 and NF-κB Seem to be Involved in Tumour Growth in an Experimental Rat Hepatoma. R. MOORE-CARRASCO, S. BUSQUETS, M. FIGUERAS, M. PALANKI, F.J. LÓPEZ-SORIANO, J.M. ARGILÉS (Barcelona, Spain; Talca, Chile; San Diego, CA, USA) .................. 1315

Role of Ape1 and Base Excision Repair in the Radioresponse and Heat-radiosensitization of HeLa Cells. C.N. BATUELLO, M.R. KELLEY, J.R. DYNLACHT (Indianapolis, IN, USA) ........................................ 1319

EGFR Inhibition Using Gefitinib Is Not Active in Neuroblastoma Cell Lines. J. RÖSSLER, E. ODENTHAL, B. GEOERGER, A. GERSTENMEYER, J. LAGODNY, C.M. NIEMEYER, G. VASSAL (Freiburg, Germany; Villejuif, France) ........................................... 1327

Matrix Metalloproteinases Are Involved in Both Type I (Apoptosis) and Type II (Autophagy) Cell Death Induced by Sodium Phenylacetate in MDA-MB-231 Breast Tumour Cells. S. AUGUSTIN, M. BERARD, S. KELLA, N. PEYRI, F. FAUVEL-LAFÈVE, C. LEGRAND, L. HE, M. CRÉPIN (Paris; Bobigny, France) .......... 1335


Contents continued on the preceding page
Apoptosis-related Factors (TRAIL, DR4, DR5, DcR1, DcR2, Apoptotic Cells) and Proliferative Activity in Ameloblastomas. C. RIZZARDI, P. LEOCATA, L. VENTURA, M. ZWEYER, A. BROLLO, M. SCHNEIDER, M. MELATO (Trieste; L'Aquila; Gorizia, Italy) ................................................................. 1137

Rapamycin Effects on mTOR Signaling in Benign, Premalignant and Malignant Human Breast Epithelial Cells. S.H. KIM, K. ZUKOWSKI, R.F. NOVAK (Detroit, MI, USA; Kangnung, South Korea) ................................................................. 1143

* Review: Genetic and Molecular Abnormalities in Cholangiocarcinogenesis. V.J. HASSID, F.A. ORLANDO, Z.T. AWAD, D. TAN, T. KHOUSEY, B.H. AHMED, S.J. ALRAWI (Jacksonville; Gainesville, FL; Houston, TX; Buffalo, NY, USA) ........................................................................................................................................................................ 1151

Increased Human Telomerase Reverse Transcriptase (hTERT) mRNA Expression but not Telomerase Activity is Related to Survival in Curatively Resected Non-small Cell Lung Cancer. R. METZGER, D. VALLBÖHMER, C. MÜLLER-TIDOW, H. HIGASHI, E. BOLLSCHEWEILER, U. WARNECKE-EBERZ, J. BRABENDER, S.E. BALDUS, H. XI, W.E. BERDEL, H. SERVE, A.H. HOELSCHER, P.M. SCHNEIDER (Cologne; Münster, Germany; Kagoshima, Japan; Beijing, China; Zurich, Switzerland) ......................................................................................................... 1157


Cisplatin Resistance of the HNSCC Cell Line UT-SCC-26A Can be Overcome by Stimulation of the EGF-Receptor. R. MANDIC, C.J. RODGARKIA-DARA, V. KROHN, S. WIEGAND, R. GRÉNMAN, J.A. WERNER (Marburg, Germany; Vienna, Austria; Turku, Finland) ........................................................................................................ 1181

Expression of Metallothionein and p53 Antigens are Correlated in Oral Squamous Cell Carcinoma. S.V. CARDOSO, J.B. SILVEIRA-JÚNIOR, V. DE CARVALHO MACHADO, A.M. BATAISTA DE PAULA, A.M. LOYOLA, M.C. FERREIRA DE AGUIAR (Uberlândia; Belo Horizonte; Montes Claros, Brazil) ................................................................................. 1189


Effect of Fucoidan on the Biotinidase Kinetics in Human Hepatocellular Carcinoma. K. HAYAKAWA, T. NAGAMINE (Tokyo; Gunma, Japan) .................................................................................. 1211

Effects of Bortezomib on Human Neuroblastoma Cells In Vitro and in a Metastatic Xenograft Model. U. VALENTINER, C. HAANE, N. NEHMANN, U. SCHUMACHER (Hamburg, Germany) .................................................................................. 1219

Down-regulation of C/EBPα in Breast Cancer Cells by Hypoxia-Estrogen Combination is Mainly Due to Hypoxia. R. SEIFEDDINE, M.-C. FULCHIGNONI-LATAUD, L. MASSAAD-MASSADE (Paris; Orsay; Villejuif, France) .................................................................................. 1227

Oct3/4 and Sox2 Are Significantly Associated with an Unfavorable Clinical Outcome in Human Esophageal Squamous Cell Carcinoma. Q. WANG, W. HE, C. LU, Z. WANG, J. WANG, K.E. GIERCKSKY, J.M. NESLAND, Z. SUO (Oslo, Norway; Dalian; Zhengzhou; Anyang, China) .................................................................................. 1233

Contents continued on the preceding page
Development of Targeted Therapy with Paclitaxel Incorporated into EGF-conjugated Nanoparticles. T. SHIMADA, M. UEDA, H. JINNO, N. CHIBA, M. WADA, J. WATANABE, K. ISHIHARA, Y. KITAGAWA (Tokyo; Osaka, Japan) ................................................. 1009

A Novel Strategy of Cancer Gene Therapy by Transcriptional Targeting of an Allogeneic Histocompatibility Transgene. E. KUWADA, K. NOGUCHI, N. SEO, H. YAMASHIRO, K. EGAWA (Tokyo; Shizuoka, Japan) .......... 1015

Up-regulation of Nuclear Receptor Corepressor (NCoR) in Progestin-induced Growth Suppression of Endometrial Hyperplasia and Carcinoma. H. KASHIMA, A. HORIZUCHI, J. UCHIKAWA, T. MIYAMOTO, A. SUZUKI, T. ASHIDA, I. KONISHI, T. SHIOZAWA (Matsumoto; Kyoto, Japan) ................................. 1023

* Review: RUNX1 Translocations in Malignant Hemopathies. E. DE BRAEKELEER, C. FÉREC, M. DE BRAEKELEER (Brest, France) .................................................................................................................. 1031

The Use of Laser Microdissection and SELDI-TOF MS in Ovarian Cancer Tissue to Identify Protein Profiles. I. CADRON, T. VAN GORP, F. AMANT, I. VERGOTE, P. MOERMAN, E. WAELKENS, A. DAEMEN, R. VAN DE PLAS, B. DE MOOR, R. ZEILLINGER (Leuven, Belgium; Vienna, Austria) ........................................ 1039


High Concentrations of Progesterone and Mifepristone Mutually Reinforce Cell Cycle Retardation and Induction of Apoptosis. B.G. MOE, A.B. VEREIDE, A. ØRBO, G. SAGER (Tromsø, Norway) .................................................................................................................. 1053

Pharmacological Interplay between Breast Cancer Resistance Protein and Gefitinib in Epidermal Growth Factor Receptor Signaling. K. KATAYAMA, K. SHIBATA, J. MITSUHASHI, K. NOGUCHI, Y. SUGIMOTO (Tokyo, Japan) .................................................................................................................. 1059

Effect of Onconase on Double-stranded RNA In Vitro. A. SAXENA, S.K. SAXENA, K. SHOGEN (Somerset, NJ, USA) ................................................................................................................................................................. 1067

The Process Behind the Expression of mdr-1/P-gp and mrp/MRP in Human Leukemia/Lymphoma. M. HIROSE (Tokushima) ................................................................................................................................................................. 1073

Heparin Induces Apoptosis through Suppression of AKt in Oral Squamous Cell Carcinoma Cells. K. UEDA, S. INOUE, Y. ZHANG, T. KUTSUNA, S. INOUE, K. NOTO, N. ARAI, M. NOGUCHI (Toyama, Japan; Beijing, China) ................................................................................................................................................................. 1079

Indirect Antitumor Effects of Bisphosphonates on Prostatic LNCaP Cells Co-cultured with Bone Cells. T. TANAKA, H. KAWASHIMA, K. OHNISHI, K. MATSUMURA, R. YOSHIMURA, M. MATSUYAMA, K. KURATSUKURI, T. NAKATANI (Osaka, Japan) .................................................................................................................. 1089

* Review: Oestrogen-synthesising Enzymes and Breast Cancer. M. KULENDRAN, M. SALHAB, K. MOKBEL (London; Uxbridge, Middlesex, UK) ................................................................................................................................. 1095

EGFR Mutation Up-regulates EGR1 Expression through the ERK Pathway. M. MAEGAWA, T. ARAO, H. YOKOTE, K. MATSUMOTO, K. KUDO, K. TANAKA, H. KANEDA, Y. FUJITA, F. ITO, K. NISHIO (Osaka, Japan) .................................................................................................................. 1111

Characterization of Phosphodiesterase 1 in Human Malignant Melanoma Cell Lines. K. SHIMIZU, T. MURATA, Y. WATANABE, C. SATO, H. MORITA, T. TAGAWA (Tsu, Mie, Japan) .................................................................................................................. 1119

Tumor-specific Cytotoxicity and Type of Cell Death Induced by Benzo[b]cyclohept[e][1,4]oxazine and 2-Aminotropone Derivatives. T. NARITA, A. SUGA, M. KOBAYASHI, K. HASHIMOTO, H. SAKAGAMI, N. MOTOHASHI, T. KURIHARA, H. WAKABAYASHI (Saitama; Tokyo, Japan) .................................................................................................................. 1123

Insulin-like Growth Factor-binding Protein-3 in Breast Cancer: Analysis with Tissue Microarray. S.-M. SHEEN-CHEN, H. ZHANG, C.-C. HUANG, R.-P. TANG (Kaohsiung; Taoyuan, Taiwan, ROC; Xiamen, China) .................................................................................................................. 1131

Contents continued on the preceding page